<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="review-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<?properties open_access?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">BMC Endocr Disord</journal-id>
<journal-id journal-id-type="iso-abbrev">BMC Endocr Disord</journal-id>
<journal-title-group>
<journal-title>BMC Endocrine Disorders</journal-title>
</journal-title-group>
<issn pub-type="epub">1472-6823</issn>
<publisher>
<publisher-name>BioMed Central</publisher-name>
<publisher-loc>London</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">27268060</article-id>
<article-id pub-id-type="pmc">4895973</article-id>
<article-id pub-id-type="publisher-id">110</article-id>
<article-id pub-id-type="doi">10.1186/s12902-016-0110-1</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Review</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Oxytocin and cardioprotection in diabetes and obesity</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Jankowski</surname>
<given-names>Marek</given-names>
</name>
<address>
<phone>1-514-890-8000</phone>
<email>marek.jankowski@umontreal.ca</email>
</address>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Broderick</surname>
<given-names>Tom L.</given-names>
</name>
<address>
<phone>1-623.572.3664</phone>
<email>tbrode@midwestern.edu</email>
</address>
<xref ref-type="aff" rid="Aff3"></xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gutkowska</surname>
<given-names>Jolanta</given-names>
</name>
<xref ref-type="aff" rid="Aff1"></xref>
<xref ref-type="aff" rid="Aff2"></xref>
</contrib>
<aff id="Aff1"><label></label>Cardiovascular Biochemistry Laboratory, CRCHUM (7-134), Tour Viger, 900 St-Denis St., Montreal, Quebec H2X 0A9 Canada </aff>
<aff id="Aff2"><label></label>Department of Medicine, Faculty of Medicine, University of Montreal, Montreal, Canada </aff>
<aff id="Aff3"><label></label>Department of Physiology, Laboratory of Diabetes and Exercise Metabolism, Midwestern University, Agave Hall, office 217-B, 19555 North 59th Avenue, Glendale, AZ 85308 USA </aff>
</contrib-group>
<pub-date pub-type="epub">
<day>7</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>7</day>
<month>6</month>
<year>2016</year>
</pub-date>
<pub-date pub-type="collection">
<year>2016</year>
</pub-date>
<volume>16</volume>
<elocation-id>34</elocation-id>
<history>
<date date-type="received">
<day>8</day>
<month>2</month>
<year>2016</year>
</date>
<date date-type="accepted">
<day>18</day>
<month>5</month>
<year>2016</year>
</date>
</history>
<permissions>
<copyright-statement>© The Author(s). 2016</copyright-statement>
<license license-type="OpenAccess">
<license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p>
</license>
</permissions>
<abstract id="Abs1">
<p>Oxytocin (OT) emerges as a drug for the treatment of diabetes and obesity. The entire OT system is synthesized in the rat and human heart. The direct myocardial infusion with OT into an ischemic or failing heart has the potential to elicit a variety of cardioprotective effects. OT treatment attenuates cardiomyocyte (CMs) death induced by ischemia-reperfusion by activating pro-survival pathways within injured CMs in vivo and in isolated cells. OT treatment reduces cardiac apoptosis, fibrosis, and hypertrophy. The OT/OT receptor (OTR) system is downregulated in the <italic>db/db</italic> mouse model of type 2 diabetes which develops genetic diabetic cardiomyopathy (DC) similar to human disease. We have shown that chronic OT treatment prevents the development of DC in the <italic>db/db</italic> mouse. In addition, OT stimulates glucose uptake in both cardiac stem cells and CMs, and increases cell resistance to diabetic conditions. OT may help replace lost CMs by stimulating the in situ differentiation of cardiac stem cells into functional mature CMs. Lastly, adult stem cells amenable for transplantation such as MSCs could be preconditioned with OT ex vivo and implanted into the injured heart to aid in tissue regeneration through direct differentiation, secretion of protective and cardiomyogenic factors and/or their fusion with injured CMs.</p>
</abstract>
<kwd-group xml:lang="en">
<title>Keywords</title>
<kwd>Oxytocin</kwd>
<kwd>Heart</kwd>
<kwd>Cardiomyocyte</kwd>
<kwd>Differentiation</kwd>
<kwd>Stem cells</kwd>
<kwd>Cardioprotection</kwd>
</kwd-group>
<funding-group>
<award-group>
<funding-source>
<institution-wrap>
<institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000028</institution-id>
<institution>Institute of Circulatory and Respiratory Health</institution>
</institution-wrap>
</funding-source>
<award-id>MOP-97992</award-id>
<principal-award-recipient>
<name>
<surname>Gutkowska</surname>
<given-names>Jolanta</given-names>
</name>
</principal-award-recipient>
</award-group>
</funding-group>
<custom-meta-group>
<custom-meta>
<meta-name>issue-copyright-statement</meta-name>
<meta-value>© The Author(s) 2016</meta-value>
</custom-meta>
</custom-meta-group>
</article-meta>
</front>
<body>
<sec id="Sec1">
<title>Background</title>
<p>OT was the first peptide hormone to have its structure determined and the first to be chemically synthesized in a biologically active form [<xref ref-type="bibr" rid="CR1">1</xref>]. OT acts as a brain neuromodulator and central nervous system (CNS) regulator functionally different than the second neurophyseal hormone, arginine-vasopressin (AVP). Both hormones are mainly produced in magnocellular cells of hypothalamic parvocellular paraventricular nucleus and supraoptic nucleus neurons [<xref ref-type="bibr" rid="CR2">2</xref>]. OT is released locally in the brain and systemically into the circulation. OT and AVP play an important role in many physiological functions through GPCR (G-protein-coupled-receptor) signal transduction. Like AVP, OT is a disulfide-bridge cyclic nonapeptide but contains neutral amino-acids at position 3 and 8 (isoleucine and leucine, respectively). The difference in polarity of these residues, compared to AVP, is believed to enable OT to interact predominantly with its specific receptor subtype [<xref ref-type="bibr" rid="CR3">3</xref>]. In humans and other mammalian species, OT and AVP target the OTR (OT receptor) and the three vasopressin receptors V1aR, V1bR and V2R. Whereas AVP binds to the OTR and AVP receptors with almost identical affinity, OT has a highest affinity for OTR and lower for AVP receptors. Study on transfected cell lines [<xref ref-type="bibr" rid="CR4">4</xref>] revealed that OT had a high affinity for the OTR (K(i) expressed as mean = 6.8 nmol/L) and bound, to some extent, to the AVP V1aR (K(i) = 34.9 nmol/L). AVP displayed higher affinities for AVP V1a, V1b and V2 receptors (K(i) = 1.4, 0.8 and 4.2 nmol/L, respectively) than for the OTR (K(i) = 48 nmol/L).</p>
<p>A single OTR can activate multiple second-messenger pathways and the OTR is found in many tissues, including the kidney, ovary, testis, pituitary, heart, vascular endothelium, adipocytes, myoblasts pancreatic islets and regulatory T cells [<xref ref-type="bibr" rid="CR3">3</xref>]. The heart, especially the right atrium is also one of the main sources of OT [<xref ref-type="bibr" rid="CR5">5</xref>].</p>
<p>Gene deletion showed that OT is essential for milk secretion and regulates maternal behavior, social recognition, sexuality, memory, pair bond formation [<xref ref-type="bibr" rid="CR6">6</xref>], and obesity [<xref ref-type="bibr" rid="CR7">7</xref>–<xref ref-type="bibr" rid="CR14">14</xref>]. OTR ligands with high specificity over the related AVP receptors are currently available and several patents propose their therapeutic utility in numerous applications, e.g. increasing lactation, acting against preterm labor, breast cancer, modulating immune system, osteoporosis, and autism-related disorders (reviewed in [<xref ref-type="bibr" rid="CR15">15</xref>]). Potential novel application of OT include treatment of autism, schizophrenia, depression, social anxiety, and Prader-Willi syndrome [<xref ref-type="bibr" rid="CR16">16</xref>]. Because OT reduces glycemia [<xref ref-type="bibr" rid="CR13">13</xref>], the potential indications for clinical use include diabetes (patents: US20140066373, D. Cai; WO 2011/14505, F. Rohner-Jeanrenaud and N. Deblon), prediabetes, and insulin resistance. In animal studies, OT has been shown to reduce food intake and produce fat weight loss and OT antagonist reverses this effect as recently reviewed [<xref ref-type="bibr" rid="CR12">12</xref>, <xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>].</p>
</sec>
<sec id="Sec2">
<title>Oxytocin signaling in the heart</title>
<p>OT is recognized as a cardiovascular hormone with cardio-protective effects [<xref ref-type="bibr" rid="CR19">19</xref>]. OT and OTR are synthesized in the human and rat heart [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR21">21</xref>] and OT exerts cardio-protection either directly or via stimulation of mediators such as the natriuretic peptides (NPs) [<xref ref-type="bibr" rid="CR20">20</xref>, <xref ref-type="bibr" rid="CR22">22</xref>] and nitric oxide (NO) [<xref ref-type="bibr" rid="CR23">23</xref>]. Both these mediators activate the cyclic guanosine 3′,5′-monophosphate/cGMP-dependent protein kinase (cGMP/PKG), following activation of soluble or particulate guanylate cyclases (sGC, pGS), respectively. The cardiovascular effects of OT include natriuresis and lowering of blood pressure, negative cardiac inotropy and chronotropy, NO-induced vasodilatation and endothelial cell growth. The cardiac OT system has been shown to regulate both cardiac cell survival pathways and provide protection against ischemic heart injury [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. It has been recently suggested that therapies enhancing the cardiac OT/OTR system prevent CMs apoptosis following an ischemia-reperfusion (IR) insult [<xref ref-type="bibr" rid="CR26">26</xref>]. CM death can be prevented or attenuated by conditioning of the heart, with OT treatment initiated either before or after an ischemic insult [<xref ref-type="bibr" rid="CR27">27</xref>]. Apart from PKG activation, NO has also been proposed as a cytoprotective factor due to the attenuation of reactive oxygen species (ROS) production during reperfusion caused by the reversible inhibition of mitochondrial respiratory complex I by S-nitrosation [<xref ref-type="bibr" rid="CR28">28</xref>]. Proposed OT signaling in CM is illustrated on Fig. <xref ref-type="fig" rid="Fig1">1</xref>. ANP is an established cardioprotective peptide because of its ability to inhibit the release of renin and sympathetic nerve activity, and the synthesis of aldosterone. ANP also ameliorates endothelial function and decreases fibrosis, inflammation and apoptosis in myocytes which are associated with LV remodeling [<xref ref-type="bibr" rid="CR29">29</xref>]. Furthermore, ANP activates the reperfusion injury salvage kinase (RISK), which has been shown to mediate ischemic preconditioning and postconditioning. OT in physiological concentrations (~10 nM) prevented the development of newborn and adult rat CMs hypertrophy exerted by ET-1 and Ang-II by several mediators such as PI3K/ERK1/2/ANP-cGMP/NFAT signalling [<xref ref-type="bibr" rid="CR30">30</xref>].<fig id="Fig1"><label>Fig. 1</label><caption><p>Proposed cardioprotective signaling of OT during ischemia reperfusion (modified from reference [<xref ref-type="bibr" rid="CR19">19</xref>]). OT acts via its G protein coupled receptors (GPCR). OT triggers the PLC-β and PI3K pathways to stimulate NO production, the regulation of ionic pumps and subsequent inhibition of the mitochondrial permeability transition pore. OT also stimulates ANP release, which in turn binds to NP receptor A to also inhibit mPTP opening. OT: oxytocin; OTR: OT receptor; PLC-β: phospholipase C type β; DAG: diacylglycerol; IP3: inositol-3-phosphate; PKC: protein kinase C; Erk1/2 : Extracellular regulated kinase 1 and 2; PI3K phosphatidylinositol-3-kinase; eNOS: endothelial nitric oxide synthase; NO: Nitric oxide; sGC: soluble guanylate cyclase; pGC: particulate guanylate cyclase; cGMP: cyclic guanosine monophosphate; PKG: protein kinase G; ROS: reactive oxygen species; mPTP: mitochondrial permeability transition pore; mitoKATP: mitochondrial ATP-dependent K<sup>+</sup> channels; CaM: Ca<sup>2+</sup>- Calmodulin; CaMKK: CaM kinase kinase; AMPK: cAMP-activated protein kinase; NPR-A: Natriuretic peptide receptor type A. 1. NHE: exchanger Na<sup>+</sup>/H<sup>+</sup> present on cell membrane; 2. Na<sup>+</sup>/K<sup>+</sup> ATPase pomp; 3. Co-transporter Na<sup>+</sup>/bicarbonate; 4. NCE: exchanger Na<sup>+</sup>/Ca<sup>2+</sup>
</p></caption><graphic id="MO1" xlink:href="12902_2016_110_Fig1_HTML"></graphic></fig></p>
</sec>
<sec id="Sec3">
<title>OT and cardioprotection</title>
<p>The role of OT in cardioprotection was recognized more than 50 years ago by Melville and Varma [<xref ref-type="bibr" rid="CR31">31</xref>] in experiments executed on rabbits. They observed that the marked ST-T depression on an electrocardiogram, resulting from hypoxia or ergometrine administration, was reduced after intravenous OT injection (1 unit/kg body weight). Interestingly, they also observed that experimental ST-T changes induced by AVP were abolished by OT co-treatment. Although the authors postulated a metabolic action of OT enhancing oxygen consumption in cardiac muscle, the presence of OTR in the heart was discovered 35 years later [<xref ref-type="bibr" rid="CR20">20</xref>]. We have recently demonstrated that OT treatment reduces lethal reperfusion injury of H9c2 cardiomyoblasts and inhibits ROS production in cells exposed to hypoxia [<xref ref-type="bibr" rid="CR25">25</xref>]. This protection of cell viability was evoked through the intact OTR because in cells with reduced OTR levels due to the siRNA-mediated knockdown, treatment with OT in I-R caused an elevated cell death compared to untreated control cells [<xref ref-type="bibr" rid="CR25">25</xref>]. It is possible that in the absence of OTR, OT triggers deleterious signaling via the AVP receptor. We would thus expect that AVP signaling is detrimental in this context, and OT is favorable. However this statement may not be accurate in view of the recent study by Phie et al. [<xref ref-type="bibr" rid="CR32">32</xref>]. They demonstrated that in the rat model of Ang II-induced hypertension, chronic co-treatment with OT failed to prevent the increase of blood pressure and LV hypertrophy. The authors observed enhanced end-organ renal injury in rats receiving a combination of OT and Ang II. Indeed, interaction of Ang II and AVP/OT in the kidney can influence cardiovascular homeostasis by several mechanisms involving V2R signaling [<xref ref-type="bibr" rid="CR33">33</xref>].</p>
<p>Several studies have presented the possibility that OT can serve as a drug for the treatment of ischemic cardiac disease [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR34">34</xref>]. OT was also shown to have transient negative inotropic and chronotropic effects on perfused isolated dog right atria mediated by NO production and acetylcholine release at cardiac parasympathetic postganglionic neurons [<xref ref-type="bibr" rid="CR35">35</xref>]. Ondrejcakova et al. [<xref ref-type="bibr" rid="CR36">36</xref>] study on isolated Langendorff-perfused rat hearts showed that the elimination through electrical stimulation of the negative chronotropic effect of OT prevented its cardioprotective action. Furthermore, the authors revealed that perfusion of the hearts with OT before ischemia resulted in significant reduction of the infarct size [<xref ref-type="bibr" rid="CR36">36</xref>]. The impaired cardiac work and down-regulation of the OT/OTR system following MI could be reversed by administration of OT given before the onset of ischemia and during one week of reperfusion in a rat model of MI [<xref ref-type="bibr" rid="CR24">24</xref>]. In the same study, we have shown that treatment with OT reduced the expression of pro-inflammatory cytokines (TNFα, IL-1β and IL-6) and reduced immune cell infiltration (especially of neutrophils) [<xref ref-type="bibr" rid="CR24">24</xref>].</p>
<p>Work by Alizadeh et al. [<xref ref-type="bibr" rid="CR34">34</xref>] showed that the reduction in infarct size in the anesthetized rat heart induced by a pre-treatment with OT (0.03 μg/kg i.p.) 25 min prior to ischemia was eliminated by the co-treatment with an inhibitor of the opening of mitoKATP channels, which have been proposed as the end-effectors of cardioprotective ischemic pre- and postconditioning. In the study of Ondrajeckova et al. [<xref ref-type="bibr" rid="CR37">37</xref>] on perfused hearts isolated from male Wistar rats treated chronically with OT, the cardioprotection was linked with specific phosphorylation (activation) of p38-MAPK and Akt kinase, an increase in phosphorylated Hsp27 and an elevation in atrial natriuretic peptide (ANP) levels in left ventricular heart tissue. Correspondingly, in H9c2 cells, the increased viability achieved by OT treatment was decreased in the presence of Wortmannin (the Pi3K-Akt pathway inhibitor), the cGMP-PKG inhibitor KT-5823, the sGC inhibitor ODQ and the pGC antagonist A71915 [<xref ref-type="bibr" rid="CR25">25</xref>]. Confocal microscopy demonstrated that following OT treatment p-Akt appeared to accumulate around the cell nuclei and co-localized with the mitochondrial marker Cox IV. It is thus possible that OT stimulates protection against ROS insult by the formation of signalosomes. This hypothesis is derived from our experiments showing that OT stimulation causes intracellular signaling involving Pi3K, Akt and eNOS [<xref ref-type="bibr" rid="CR38">38</xref>], known as the canonical factors of signalosomes derived from GPCR [<xref ref-type="bibr" rid="CR39">39</xref>].</p>
<p>We have also observed the paradox that OT treatment stimulates the production of moderate levels of ROS whereas OT inhibits excess ROS produced as a consequence of ischemia [<xref ref-type="bibr" rid="CR25">25</xref>]. The high levels of ROS are detrimental for CMs but moderate levels of ROS function as signaling molecules for cardioprotection by activating protein kinases such as Pi3K/Akt within and outside the mitochondria [<xref ref-type="bibr" rid="CR40">40</xref>], as well as the ERK1/2, MAPK p38 and/or JAK/STAT prosurvival signalling cascade [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR41">41</xref>].</p>
</sec>
<sec id="Sec4">
<title>Obesity and OT treatment</title>
<p>Several key metabolic effects of OT have been reported such as anti-inflammatory activity, wound healing, antioxidant activity and increase of glucose uptake in cardiac and stem cells [<xref ref-type="bibr" rid="CR19">19</xref>]. The adult male OTR-deficient mice [<xref ref-type="bibr" rid="CR14">14</xref>] and both male and female OT knockout mice [<xref ref-type="bibr" rid="CR42">42</xref>] express a mild obese phenotype. Zhang et al. [<xref ref-type="bibr" rid="CR43">43</xref>] have shown that C57BL/6 mice fed a high fat diet (HFD) became obese and showed reduced plasma OT levels. Lowered OT levels in the circulation are also reported in human diabetes type 1 and 2 [<xref ref-type="bibr" rid="CR44">44</xref>, <xref ref-type="bibr" rid="CR45">45</xref>]. Chronic OT administration protected against HFD-induced obesity in rodent models [<xref ref-type="bibr" rid="CR7">7</xref>, <xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR46">46</xref>]. A recent study of Blevins et al. [<xref ref-type="bibr" rid="CR47">47</xref>] indicates that chronic that a chronic increase (≈21–26 days) of CNS oxytocin signalling not only prevented weight gain induced by HFD but also effectively reduced already established diet-induced obesity. OT also decreased the genetic-induced obesity observed in Zucker rats [<xref ref-type="bibr" rid="CR48">48</xref>] and <italic>db/db</italic> mice models [<xref ref-type="bibr" rid="CR49">49</xref>], which bear a mutation in the leptin receptor gene.</p>
<p>OT has many positive metabolic effects based on remarkable changes in glucose metabolism, lipid profile, and insulin sensitivity after OT administration. OT dose-dependently reduces food intake in animal and human studies (reviewed in [<xref ref-type="bibr" rid="CR17">17</xref>]). Importantly, OT treatment improves eating behaviors such that hedonic hyperphagia is reduced and does not interfere with normal hunger and weight regulation [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR46">46</xref>, <xref ref-type="bibr" rid="CR50">50</xref>, <xref ref-type="bibr" rid="CR51">51</xref>]. The <italic>ob/ob</italic> mouse represents a close counterpart to the human condition of severe obesity, but unlike <italic>db/db</italic> mice, exhibit leptin deficiency from a mutation in the <italic>ob</italic>-gene [<xref ref-type="bibr" rid="CR52">52</xref>]. Ironically, a recent study revealed that OT treatment of <italic>ob/ob</italic> mice worsened glycemic control, likely from an increased production of corticosterone and stimulation of hepatic gluconeogenesis [<xref ref-type="bibr" rid="CR50">50</xref>]. The body weight gain-reducing effect was limited to the fat mass only, with decreased lipid uptake, lipogenesis, and inflammation, combined with increased futile cycling in abdominal adipose tissue. Correspondingly, several clinical trials (UKPDS33, ACCORD, ADVANCE, and VADT) demonstrated that intensive glycemic control fails to prevent cardiac complications in diabetics or have even increased cardiovascular mortality [<xref ref-type="bibr" rid="CR53">53</xref>]. This calls for the development of new strategies capable of preserving heart function in diabetes.</p>
<p>OT intranasal delivery, secure for the treatment in humans, appears to effectively enable OT to enter the CNS in mice, rats, nonhuman primates and humans within 30–35 min post-treatment [<xref ref-type="bibr" rid="CR54">54</xref>–<xref ref-type="bibr" rid="CR56">56</xref>]. Intranasal OT administration increases OT levels also by stimulation of endogenous synthesis [<xref ref-type="bibr" rid="CR54">54</xref>, <xref ref-type="bibr" rid="CR57">57</xref>], resulting in the prolongation of the OT half-life and efficacy [<xref ref-type="bibr" rid="CR58">58</xref>]. This mode of delivery may also increase OT levels in the circulation if the intranasal delivery device did not sufficiently target the cribiform plate [<xref ref-type="bibr" rid="CR59">59</xref>]. In a recent study, intranasal OT administration in patients receiving 24 units 4×/day (1 unit ~ 1.7 μg; 1.77 μg/kg body weight/day) over a period of eight-weeks reduced obesity and reversed prediabetic changes [<xref ref-type="bibr" rid="CR13">13</xref>]. We found that increases in both energy expenditure and brown adipose tissue volume contribute to the decrease of body mass of OT-treated <italic>db/db</italic> mice [<xref ref-type="bibr" rid="CR49">49</xref>].</p>
</sec>
<sec id="Sec5">
<title>The role of exercise in obesity and diabetes</title>
<p>Weight loss improves cardiac function in obesity [<xref ref-type="bibr" rid="CR60">60</xref>] and especially exercise training reduces events of HF [<xref ref-type="bibr" rid="CR61">61</xref>]. There is substantial evidence to support the value of regular exercise training in patients with obesity and diabetes [<xref ref-type="bibr" rid="CR62">62</xref>]. Exercise improves overall cardiorespiratory fitness and decreases the risk of developing cardiac and vascular injury [<xref ref-type="bibr" rid="CR63">63</xref>]. Exercise training is also associated with an increase in peripheral glucose utilization and reduction in white adipose tissue (WAT) content. WAT is source of leptin, which acts on its hypothalamic receptors to regulate energy use and induce satiety [<xref ref-type="bibr" rid="CR64">64</xref>]. WAT mRNA expression is increased in human obesity as well as in relevant rodent models [<xref ref-type="bibr" rid="CR65">65</xref>, <xref ref-type="bibr" rid="CR66">66</xref>], and chronically elevated blood levels of this peptide is known to induce leptin resistance [<xref ref-type="bibr" rid="CR67">67</xref>], leading to a loss of appetite suppression and decreased energy production. Further, epidemiological studies indicate that plasma hyperleptinemia is an independent predictor of CV events [<xref ref-type="bibr" rid="CR68">68</xref>]. Elevated WAT promotes the secretion of monocyte chemotactic factor-1 (MCP-1), which promotes infiltration of macrophages into WAT [<xref ref-type="bibr" rid="CR69">69</xref>], increased expression of TNF-α and IL-6, and decreased expression of adiponectin. This abnormal cytokine pattern is known to attenuate insulin signaling responses in tissues, leading to insulin resistance [<xref ref-type="bibr" rid="CR70">70</xref>]. In diet-induced obesity, running activity decreases the expression of mRNA for leptin in both visceral adipose tissue and WAT [<xref ref-type="bibr" rid="CR71">71</xref>, <xref ref-type="bibr" rid="CR72">72</xref>]. However, the effects of regular exercise on WAT and leptin content in plasma of humans are inconsistent, largely due to differences in the exercise program, duration of intervention, pre-exercise body and fat mass index, and whether exercise is combined with diet restriction [<xref ref-type="bibr" rid="CR73">73</xref>].</p>
</sec>
<sec id="Sec6">
<title>The cardiac OT/OTR system and exercise</title>
<p>The cardiac OT system is downregulated in DC [<xref ref-type="bibr" rid="CR74">74</xref>], MI [<xref ref-type="bibr" rid="CR24">24</xref>], and hypertension [<xref ref-type="bibr" rid="CR75">75</xref>] suggesting that OTR deficiency magnifies these pathologies. Lowered OT plasma levels are also linked to increased sensitivity of cardiovascular system to stress [<xref ref-type="bibr" rid="CR76">76</xref>]. Interestingly, down-regulation of the OT/OTR system (which includes natriuretic peptides (NPs) ANP, BNP) in the LV of ovariectomized rats can be effectively prevented by regular exercise training [<xref ref-type="bibr" rid="CR19">19</xref>]. Indeed, hypothalamic and LV mRNA levels of OT, OTR, and NPs were restored back to normal levels after 8-weeks of moderate intensity exercise training on a treadmill. We have investigated the effects of exercise training in the <italic>db/db</italic> mice, a mouse model of diabetes and obesity used to study DC. These mice display genetic mutations in leptin receptor, resulting in a diabetic profile induced by hyperphagia. We have demonstrated that exercise training failed to upregulate of the OT/OTR system in hearts of <italic>db/db</italic> mice. After eight weeks of moderate intensity treadmill running, mRNA expression of the OT/OTR system in <italic>db/db</italic> hearts remained low and unchanged from pre-training levels [<xref ref-type="bibr" rid="CR74">74</xref>]. Expression of ANP and BNP was similarity low and even further decreased after exercise training, and training had no effect on the extent of obesity and blood glucose concentrations [<xref ref-type="bibr" rid="CR72">72</xref>], suggesting that the hyperglycemic state may contribute to reduced expression of OT and NPs. This hypothesis was suggested earlier by Kobayashi et al. [<xref ref-type="bibr" rid="CR77">77</xref>] indicating that acute hyperglycemic conditions and streptozotocin-induced type 1 diabetes reduced the expression of GATA4, a transcription factor associated with the synthesis of structural and cardioprotective genes, including OT/OTR and NPs [<xref ref-type="bibr" rid="CR78">78</xref>]. Hearts from <italic>db/db</italic> mice exhibited low mRNA and protein levels of GATA4 [<xref ref-type="bibr" rid="CR79">79</xref>], and exercise training was beneficial in stimulating GATA4 protein expression, albeit in the absence of the OT/OTR system. Degradation of GATA4 by hyperglycemia is induced by ROS and ubiquitination by ubiquitin-proteaosomes [<xref ref-type="bibr" rid="CR80">80</xref>], and a benefit of exercise may be related to reduced expression of E3-ubiquitin ligase MURF1 [<xref ref-type="bibr" rid="CR81">81</xref>]. The possibility exists that GATA4 is not required and that expression of another transcription factor, such as GATA6 [<xref ref-type="bibr" rid="CR82">82</xref>], is involved in the synthesis of OT and NPs. The role of GATA4 and exercise training on the OT/OTR system is further complicated by our recent findings showing that expression of this transcription factor is not altered by the effects of hyperglycemia or obesity in hearts of <italic>ob/ob</italic> mice [<xref ref-type="bibr" rid="CR83">83</xref>]. Eight weeks of spontaneous running in <italic>ob/ob</italic> mice increased cardiac mRNA expression of GATA4, but disrupted glucose and triglyceride regulation. Consistent with the gene profile observed in <italic>db/db</italic> mice after exercise training, expression of OTR, ANP, BNP, and C-type NP was reduced. One important aspect that arises from this <italic>ob/ob</italic> study is whether leptin is key to this aberrant synthesis of the OT/OTR system. In addition to its well-established role in appetite control, leptin is known for stimulating running activity in mice [<xref ref-type="bibr" rid="CR84">84</xref>].</p>
</sec>
<sec id="Sec7">
<title>Normalization of OT plasma levels and upregulation of the cardiac OT/OTR system protects the heart against DC</title>
<p>OT treatment in four-week old <italic>db/db</italic> diabetic mice for a period of 12 weeks improved body parameters, metabolic parameters (including insulin resistance) and protected against systolic and diastolic cardiac dysfunction, ROS production, apoptosis and fibrosis [<xref ref-type="bibr" rid="CR49">49</xref>]. OT treatment prevented the reduction in cardiac <italic>ANP</italic> and <italic>BNP</italic> gene expression in <italic>db/db</italic> mice as well as <italic>Gata4,</italic> the transcription factor of genes required in the maintenance of cardiac structure and function [<xref ref-type="bibr" rid="CR85">85</xref>]. BNP treatment in <italic>db/db</italic> mice also reduced CM hypertrophy and increased local OT/OTR expression [<xref ref-type="bibr" rid="CR82">82</xref>]. OT treatment resulted in activation of Akt-1 in cardiac cells which targets an array of diverse cellular functions, including stimulate NO production, protein synthesis, energy metabolism, and cellular survival [<xref ref-type="bibr" rid="CR86">86</xref>]. OT also increased the activity of AMP-activated protein kinase (AMPK) and induced the expression of cardioprotective genes [<xref ref-type="bibr" rid="CR38">38</xref>]. OT treated <italic>db/db</italic> mice displayed decrease in expression of cardiac inflammatory markers, including NF-kB, the IL-1β and IL-6. The marked improvement of the cardiac work and structure, measured by echocardiography, was achieved by OT treatment in spite of a modest reduction of glycemia [<xref ref-type="bibr" rid="CR49">49</xref>]. We found that increases in both energy expenditure and brown adipose tissue volume contribute to the decrease of body mass of OT-treated <italic>db/db</italic> mice [<xref ref-type="bibr" rid="CR49">49</xref>]. A recent study reports the contribution of the OT system in the alleviation of obesity and reduction of glycemia by retinoic acid treatment in leptin-deficient, <italic>ob/ob</italic> obese diabetic mice [<xref ref-type="bibr" rid="CR87">87</xref>]. These results suggest the usefulness of OT as a therapeutic alternative because it bypasses the defective insulin-signaling pathway(s) in subjects with type 2 diabetes with obesity.</p>
<p>The mechanisms responsible for cardiac protection by OT against DC are not yet understood. It is unclear whether OT acts via a number of organs and tissues, or specifically enhances OT/OTR signaling in cardiac cells.</p>
</sec>
<sec id="Sec8" sec-type="materials|methods">
<title>Oxytocin treatment provides a method of regenerating cardiac tissue</title>
<p>Some evidence indicates that the heart, long considered to be a terminally differentiated organ, contains CM-like cells which undergo mitosis, as reported in patients with acute myocardial injury [<xref ref-type="bibr" rid="CR88">88</xref>]. These cells are defined as cardiac progenitor cells (CPCs) and may contribute in cardiac reparative processes [<xref ref-type="bibr" rid="CR89">89</xref>]. Diabetes exerts a detrimental effect on the proliferation and survival of CPCs in both humans and animal models of diabetes [<xref ref-type="bibr" rid="CR90">90</xref>]. Similarly, aging and diabetes mellitus also have been shown to correlate negatively with other stem cell types such as MSCs [<xref ref-type="bibr" rid="CR91">91</xref>] and endothelial progenitor cells (EPC) [<xref ref-type="bibr" rid="CR92">92</xref>].</p>
<p>Oxidative stress induces senescence of CPCs in diabetic cardiomyopathy [<xref ref-type="bibr" rid="CR93">93</xref>]. It is suggested that the premature aging of cardiac stem leads to the development of HF [<xref ref-type="bibr" rid="CR94">94</xref>]. The loss of cardiac cells is accompanied by a decrease in cardiac muscle mass, chamber dilation, and impaired ventricular function [<xref ref-type="bibr" rid="CR95">95</xref>]. Recent reports suggest that senescent CPCs from a diseased heart can be activated and reverted to the “young” phenotype by treatment with factors that change cellular signaling [<xref ref-type="bibr" rid="CR96">96</xref>]. OT stimulates the proliferation of cardiac stem cells [<xref ref-type="bibr" rid="CR97">97</xref>, <xref ref-type="bibr" rid="CR98">98</xref>], and also their differentiation to CMs and ECs [<xref ref-type="bibr" rid="CR19">19</xref>]. The expression of the OT/OTR system correlates with youthful cardiac phenotypic characteristics [<xref ref-type="bibr" rid="CR21">21</xref>], and it is possible that diabetes-related changes in viability, morphology and proliferation can be reduced by OT treatment.</p>
<p>MSCs are able to hone in on the injured heart, to engraft into damaged blood vessels, to differentiate into cardiac cells, and to exert a paracrine effect by the local release of vascular growth factors and cytokines [<xref ref-type="bibr" rid="CR99">99</xref>]. Recent studies have shown that direct injection with OT-treated MSCs into the rat heart after ischemia-reperfusion injury improves their engraftment rate and results in an enhanced cardioprotective effect via increased transmigration activity to the injured zone, the upregulation of matrix metalloproteinase-2 mRNA, the integration of MSCs into the myocardium [<xref ref-type="bibr" rid="CR100">100</xref>]. OT stimulates in these cells the production of paracrine anti-fibrotic and anti-inflammatory factors [<xref ref-type="bibr" rid="CR98">98</xref>]. For improving survival, proliferation, and differentiation MSC in diabetic conditions either in vitro or after transplantation in pre-clinical models, Kim et al. proposed OT as a priming reagent restoring the angiogenesis activity of MSC [<xref ref-type="bibr" rid="CR101">101</xref>].</p>
</sec>
<sec id="Sec9">
<title>Conclusions</title>
<p>Several investigations have clearly established the role of OT in lowering of body weight by mechanisms involving increased energy expenditure, reduced adiposity and food intake. In models of diabetes and obesity as well as in human diabetes, OT deficiency has been reported. Improvement in body weight and composition can be obtained by central, peripheral and intranasal OT administration. In addition, an OT effect as a prosocial hormone may provide additional benefit in the treatment of complex diseases such as diabetes and metabolic syndrome. Preclinical studies on animal models have demonstrated that OT limits myocardial ischemia and reperfusion injury, independent from its glucose-lowering effect. The OT-mediated cardioprotection include activation of the NPs and NO both increasing formation of cGMP in the heart, activation of AMPK and by inhibition of excess of ROS produced as a consequence of ischemia. The potential OT benefit in diabetic cardiomyopathy is illustrated on Fig. <xref ref-type="fig" rid="Fig2">2</xref>. Exercise training increases the OT/OTR system in the ovariectomized-rat, but the role of exercise on this system in obesity and diabetes remain poorly understood. The major clinical consequence of diastolic dysfunction is exertional dyspnea, which impedes the capacity of diabetic individuals to perform exercise, an important aspect of diabetes management, particularly in the obesity [<xref ref-type="bibr" rid="CR102">102</xref>]. Considering the efficacy of intranasal OT delivery in stimulating the synthesis of central and peripheral OT, and in reducing obesity and hedonic eating habits, investigation into the role of combined intranasal OT treatment and exercise training are warranted. Consequently, treatment with OT might potentially improve cardiovascular outcome in patients at risk for heart failure especially in association with obesity and diabetes.<fig id="Fig2"><label>Fig. 2</label><caption><p>Oxytocin (OT) treatment in diabetes protects against diabetic cardiomyopathy The mechanism involve direct OT effect on the heart and release of atrial natriuretic peptide (ANP) and nitric oxide (NO) as well as their second messenger cyclic guanylate cyclase (cGMP). OT reduces fat deposits through decrease of adipocytes size and brown fat production. Adipocytes release adipokines to the circulation which are beneficial for the heart. In pancreas OT stimulates insulin release</p></caption><graphic id="MO2" xlink:href="12902_2016_110_Fig2_HTML"></graphic></fig></p>
</sec>
</body>
<back>
<ack>
<title>Acknowledgements</title>
<p>Sources of funding: this study was supported in part by the Canadian Institutes of Health Research and the Canadian Heart and Stroke Foundation.</p>
<sec id="FPar1">
<title>Authors’ contributions</title>
<p>MJ and TLB have equally contributed in design and writing of manuscript therefore they are proposed as the equal first and corresponding authors. JG supervised and critically evaluated concept and execution of this manuscript. All authors read and approved the final manuscript.</p>
</sec>
<sec id="FPar2">
<title>Competing interests</title>
<p>The authors declare that they have no competing interests.</p>
</sec>
</ack>
<ref-list id="Bib1">
<title>References</title>
<ref id="CR1">
<label>1.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Du Vigneaud</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Ressler</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Trippett</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>The sequence of amino acids in oxytocin, with a proposal for the structure of oxytocin</article-title>
<source/>J Biol Chem
          <year>1953</year>
<volume>205</volume>
<issue>2</issue>
<fpage>949</fpage>
<lpage>957</lpage>
<pub-id pub-id-type="pmid">13129273</pub-id>
</element-citation>
</ref>
<ref id="CR2">
<label>2.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meyer-Lindenberg</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Domes</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Kirsch</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Heinrichs</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Oxytocin and vasopressin in the human brain: social neuropeptides for translational medicine</article-title>
<source/>Nat Rev Neurosci
          <year>2011</year>
<volume>12</volume>
<issue>9</issue>
<fpage>524</fpage>
<lpage>538</lpage>
<pub-id pub-id-type="doi">10.1038/nrn3044</pub-id>
<pub-id pub-id-type="pmid">21852800</pub-id>
</element-citation>
</ref>
<ref id="CR3">
<label>3.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gimpl</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Fahrenholz</surname>
<given-names>F</given-names>
</name>
</person-group>
<article-title>The oxytocin receptor system: structure, function, and regulation</article-title>
<source/>Physiol Rev
          <year>2001</year>
<volume>81</volume>
<issue>2</issue>
<fpage>629</fpage>
<lpage>683</lpage>
<pub-id pub-id-type="pmid">11274341</pub-id>
</element-citation>
</ref>
<ref id="CR4">
<label>4.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Akerlund</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bossmar</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Brouard</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Kostrzewska</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Laudanski</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Lemancewicz</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Receptor binding of oxytocin and vasopressin antagonists and inhibitory effects on isolated myometrium from preterm and term pregnant women</article-title>
<source/>Br J Obstet Gynaecol
          <year>1999</year>
<volume>106</volume>
<issue>10</issue>
<fpage>1047</fpage>
<lpage>1053</lpage>
<pub-id pub-id-type="doi">10.1111/j.1471-0528.1999.tb08112.x</pub-id>
<pub-id pub-id-type="pmid">10519430</pub-id>
</element-citation>
</ref>
<ref id="CR5">
<label>5.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Hajjar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kawas</surname>
<given-names>SA</given-names>
</name>
<name>
<surname>Mukaddam-Daher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hoffman</surname>
<given-names>G</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>SM</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rat heart: a site of oxytocin production and action</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1998</year>
<volume>95</volume>
<issue>24</issue>
<fpage>14558</fpage>
<lpage>14563</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.95.24.14558</pub-id>
<pub-id pub-id-type="pmid">9826739</pub-id>
</element-citation>
</ref>
<ref id="CR6">
<label>6.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Stevens</surname>
<given-names>FL</given-names>
</name>
<name>
<surname>Weisman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Feldman</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Hurley</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Taber</surname>
<given-names>KH</given-names>
</name>
</person-group>
<article-title>Oxytocin and behavior: evidence for effects in the brain</article-title>
<source/>J Neuropsychiatry Clin Neurosci
          <year>2013</year>
<volume>25</volume>
<issue>2</issue>
<fpage>96</fpage>
<lpage>102</lpage>
<pub-id pub-id-type="doi">10.1176/appi.neuropsych.13030061</pub-id>
<pub-id pub-id-type="pmid">23686025</pub-id>
</element-citation>
</ref>
<ref id="CR7">
<label>7.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Deblon</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Veyrat-Durebex</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Bourgoin</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Caillon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Bussier</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Petrosino</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Mechanisms of the anti-obesity effects of oxytocin in diet-induced obese rats</article-title>
<source/>PLoS One
          <year>2011</year>
<volume>6</volume>
<issue>9</issue>
<fpage>e25565</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0025565</pub-id>
<pub-id pub-id-type="pmid">21980491</pub-id>
</element-citation>
</ref>
<ref id="CR8">
<label>8.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maejima</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Iwasaki</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Yamahara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kodaira</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Sedbazar</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Yada</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Peripheral oxytocin treatment ameliorates obesity by reducing food intake and visceral fat mass</article-title>
<source/>Aging
          <year>2011</year>
<volume>3</volume>
<issue>12</issue>
<fpage>1169</fpage>
<lpage>1177</lpage>
<pub-id pub-id-type="doi">10.18632/aging.100408</pub-id>
<pub-id pub-id-type="pmid">22184277</pub-id>
</element-citation>
</ref>
<ref id="CR9">
<label>9.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Tolson</surname>
<given-names>KP</given-names>
</name>
<name>
<surname>Gemelli</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Gautron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Elmquist</surname>
<given-names>JK</given-names>
</name>
<name>
<surname>Zinn</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Kublaoui</surname>
<given-names>BM</given-names>
</name>
</person-group>
<article-title>Postnatal Sim1 deficiency causes hyperphagic obesity and reduced Mc4r and oxytocin expression</article-title>
<source/>J Neurosci Off J Soc Neurosci
          <year>2010</year>
<volume>30</volume>
<issue>10</issue>
<fpage>3803</fpage>
<lpage>3812</lpage>
<pub-id pub-id-type="doi">10.1523/JNEUROSCI.5444-09.2010</pub-id>
</element-citation>
</ref>
<ref id="CR10">
<label>10.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Cai</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Circadian intervention of obesity development via resting-stage feeding manipulation or oxytocin treatment</article-title>
<source/>Am J Physiol Endocrinol Metab
          <year>2011</year>
<volume>301</volume>
<issue>5</issue>
<fpage>E1004</fpage>
<lpage>1012</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00196.2011</pub-id>
<pub-id pub-id-type="pmid">21828335</pub-id>
</element-citation>
</ref>
<ref id="CR11">
<label>11.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Dombret</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Schakman</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Michaud</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Hardin-Pouzet</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Bertrand</surname>
<given-names>MJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Loss of Maged1 results in obesity, deficits of social interactions, impaired sexual behavior and severe alteration of mature oxytocin production in the hypothalamus</article-title>
<source/>Hum Mol Genet
          <year>2012</year>
<volume>21</volume>
<issue>21</issue>
<fpage>4703</fpage>
<lpage>4717</lpage>
<pub-id pub-id-type="doi">10.1093/hmg/dds310</pub-id>
<pub-id pub-id-type="pmid">22865874</pub-id>
</element-citation>
</ref>
<ref id="CR12">
<label>12.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cai</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Purkayastha</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes</article-title>
<source/>Drug discov today Dis mech
          <year>2013</year>
<volume>10</volume>
<issue>1-2</issue>
<fpage>e63</fpage>
<lpage>e68</lpage>
<pub-id pub-id-type="doi">10.1016/j.ddmec.2013.05.006</pub-id>
<pub-id pub-id-type="pmid">24159336</pub-id>
</element-citation>
</ref>
<ref id="CR13">
<label>13.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Treatment of obesity and diabetes using oxytocin or analogs in patients and mouse models</article-title>
<source/>PLoS One
          <year>2013</year>
<volume>8</volume>
<issue>5</issue>
<fpage>e61477</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0061477</pub-id>
<pub-id pub-id-type="pmid">23700406</pub-id>
</element-citation>
</ref>
<ref id="CR14">
<label>14.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Takayanagi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Kasahara</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Onaka</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Kawada</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nishimori</surname>
<given-names>K</given-names>
</name>
</person-group>
<article-title>Oxytocin receptor-deficient mice developed late-onset obesity</article-title>
<source/>Neuroreport
          <year>2008</year>
<volume>19</volume>
<issue>9</issue>
<fpage>951</fpage>
<lpage>955</lpage>
<pub-id pub-id-type="doi">10.1097/WNR.0b013e3283021ca9</pub-id>
<pub-id pub-id-type="pmid">18520999</pub-id>
</element-citation>
</ref>
<ref id="CR15">
<label>15.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gimpl</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Oxytocin receptor ligands: a survey of the patent literature</article-title>
<source/>Expert Opin Therapeutic Patents
          <year>2008</year>
<volume>18</volume>
<issue>11</issue>
<fpage>1239</fpage>
<lpage>1251</lpage>
<pub-id pub-id-type="doi">10.1517/13543776.18.11.1239</pub-id>
</element-citation>
</ref>
<ref id="CR16">
<label>16.</label>
<mixed-citation publication-type="other">Spetter MS, Hallschmid M. Intranasal neuropeptide administration to target the human brain in health and disease. Mol Pharm. 2015;12(8):2767–80. doi:10.1021/acs.molpharmaceut.5b00047.</mixed-citation>
</ref>
<ref id="CR17">
<label>17.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blevins</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Morton</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Bales</surname>
<given-names>KL</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic oxytocin administration inhibits food intake, increases energy expenditure, and produces weight loss in fructose-fed obese rhesus monkeys</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
          <year>2015</year>
<volume>308</volume>
<issue>5</issue>
<fpage>R431</fpage>
<lpage>438</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.00441.2014</pub-id>
<pub-id pub-id-type="pmid">25540103</pub-id>
</element-citation>
</ref>
<ref id="CR18">
<label>18.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Elabd</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Sabry</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>Two Birds with One Stone: Possible Dual-Role of Oxytocin in the Treatment of Diabetes and Osteoporosis</article-title>
<source/>Front Endocrinol
          <year>2015</year>
<volume>6</volume>
<fpage>121</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2015.00121</pub-id>
</element-citation>
</ref>
<ref id="CR19">
<label>19.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Oxytocin revisited: its role in cardiovascular regulation</article-title>
<source/>J Neuroendocrinol
          <year>2012</year>
<volume>24</volume>
<issue>4</issue>
<fpage>599</fpage>
<lpage>608</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2826.2011.02235.x</pub-id>
<pub-id pub-id-type="pmid">21981277</pub-id>
</element-citation>
</ref>
<ref id="CR20">
<label>20.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Mukaddam-Daher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zingg</surname>
<given-names>HH</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Oxytocin releases atrial natriuretic peptide by combining with oxytocin receptors in the heart</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1997</year>
<volume>94</volume>
<issue>21</issue>
<fpage>11704</fpage>
<lpage>11709</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.94.21.11704</pub-id>
<pub-id pub-id-type="pmid">9326674</pub-id>
</element-citation>
</ref>
<ref id="CR21">
<label>21.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Bhat</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hajjar</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Marcinkiewicz</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin in cardiac ontogeny</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2004</year>
<volume>101</volume>
<issue>35</issue>
<fpage>13074</fpage>
<lpage>13079</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0405324101</pub-id>
<pub-id pub-id-type="pmid">15316117</pub-id>
</element-citation>
</ref>
<ref id="CR22">
<label>22.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Mukaddam-Daher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>McCann</surname>
<given-names>SM</given-names>
</name>
</person-group>
<article-title>Oxytocin is a cardiovascular hormone</article-title>
<source/>Braz J Med Biol Res
          <year>2000</year>
<volume>33</volume>
<issue>6</issue>
<fpage>625</fpage>
<lpage>633</lpage>
<pub-id pub-id-type="doi">10.1590/S0100-879X2000000600003</pub-id>
<pub-id pub-id-type="pmid">10829090</pub-id>
</element-citation>
</ref>
<ref id="CR23">
<label>23.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Danalache</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Paquin</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Donghao</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Grygorczyk</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>JC</given-names>
</name>
<name>
<surname>Mummery</surname>
<given-names>CL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Nitric oxide signaling in oxytocin-mediated cardiomyogenesis</article-title>
<source/>Stem Cells
          <year>2007</year>
<volume>25</volume>
<issue>3</issue>
<fpage>679</fpage>
<lpage>688</lpage>
<pub-id pub-id-type="doi">10.1634/stemcells.2005-0610</pub-id>
<pub-id pub-id-type="pmid">17138963</pub-id>
</element-citation>
</ref>
<ref id="CR24">
<label>24.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bissonauth</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Gao</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Gangal</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>B</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Anti-inflammatory effect of oxytocin in rat myocardial infarction</article-title>
<source/>Basic Res Cardiol
          <year>2010</year>
<volume>105</volume>
<issue>2</issue>
<fpage>205</fpage>
<lpage>218</lpage>
<pub-id pub-id-type="doi">10.1007/s00395-009-0076-5</pub-id>
<pub-id pub-id-type="pmid">20012748</pub-id>
</element-citation>
</ref>
<ref id="CR25">
<label>25.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gonzalez-Reyes</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Menaouar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Plante</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Noiseux</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Molecular mechanisms underlying oxytocin-induced cardiomyocyte protection from simulated ischemia-reperfusion</article-title>
<source/>Mol Cell Endocrinol
          <year>2015</year>
<volume>412</volume>
<fpage>170</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1016/j.mce.2015.04.028</pub-id>
<pub-id pub-id-type="pmid">25963797</pub-id>
</element-citation>
</ref>
<ref id="CR26">
<label>26.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kung</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Konstantinidis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kitsis</surname>
<given-names>RN</given-names>
</name>
<name>
<surname>Kung</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Konstantinidis</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kitsis</surname>
<given-names>RN</given-names>
</name>
</person-group>
<article-title>Programmed necrosis, not apoptosis, in the heart</article-title>
<source/>Circ Res
          <year>2011</year>
<volume>108</volume>
<issue>8</issue>
<fpage>1017</fpage>
<lpage>1036</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.225730</pub-id>
<pub-id pub-id-type="pmid">21493924</pub-id>
</element-citation>
</ref>
<ref id="CR27">
<label>27.</label>
<mixed-citation publication-type="other">Das B, Sarkar C. Is preconditioning by oxytocin administration mediated by iNOS and/or mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart? Life Sci. 2012; 90(19–20):763–769. doi:10.10.1016/j.lfs.2012.03.030.</mixed-citation>
</ref>
<ref id="CR28">
<label>28.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heusch</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Boengler</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schulz</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Cardioprotection: nitric oxide, protein kinases, and mitochondria</article-title>
<source/>Circulation
          <year>2008</year>
<volume>118</volume>
<issue>19</issue>
<fpage>1915</fpage>
<lpage>1919</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.108.805242</pub-id>
<pub-id pub-id-type="pmid">18981312</pub-id>
</element-citation>
</ref>
<ref id="CR29">
<label>29.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kasama</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Furuya</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Toyama</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ichikawa</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Krabayashi</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Effect of atrial natriuretic peptide on left ventricular remodelling in patients with acute myocardial infarction</article-title>
<source/>Eur Heart J
          <year>2008</year>
<volume>29</volume>
<fpage>1485</fpage>
<lpage>1494</lpage>
<pub-id pub-id-type="doi">10.1093/eurheartj/ehn206</pub-id>
<pub-id pub-id-type="pmid">18490430</pub-id>
</element-citation>
</ref>
<ref id="CR30">
<label>30.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Menaouar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Florian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Anti-hypertrophic effects of oxytocin in rat ventricular myocytes</article-title>
<source/>Int J Cardiol
          <year>2014</year>
<volume>175</volume>
<issue>1</issue>
<fpage>38</fpage>
<lpage>49</lpage>
<pub-id pub-id-type="doi">10.1016/j.ijcard.2014.04.174</pub-id>
<pub-id pub-id-type="pmid">24852833</pub-id>
</element-citation>
</ref>
<ref id="CR31">
<label>31.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Melville</surname>
<given-names>KI</given-names>
</name>
<name>
<surname>Varma</surname>
<given-names>DR</given-names>
</name>
</person-group>
<article-title>Synthetic oxytocin as an antagonist of experimental cardiac anoxic changes in rabbits</article-title>
<source/>Br J Pharmacol Chemother
          <year>1961</year>
<volume>17</volume>
<fpage>218</fpage>
<lpage>223</lpage>
<pub-id pub-id-type="doi">10.1111/j.1476-5381.1961.tb01281.x</pub-id>
<pub-id pub-id-type="pmid">14472482</pub-id>
</element-citation>
</ref>
<ref id="CR32">
<label>32.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Phie</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Haleagrahara</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Newton</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Constantinoiu</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Sarnyai</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Chilton</surname>
<given-names>L</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Prolonged Subcutaneous Administration of Oxytocin Accelerates Angiotensin II-Induced Hypertension and Renal Damage in Male Rats</article-title>
<source/>PLoS One
          <year>2015</year>
<volume>10</volume>
<issue>9</issue>
<fpage>e0138048</fpage>
<pub-id pub-id-type="doi">10.1371/journal.pone.0138048</pub-id>
<pub-id pub-id-type="pmid">26393919</pub-id>
</element-citation>
</ref>
<ref id="CR33">
<label>33.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schrier</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Interactions between angiotensin II and arginine vasopressin in water homeostasis</article-title>
<source/>Kidney Int
          <year>2009</year>
<volume>76</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>139</lpage>
<pub-id pub-id-type="doi">10.1038/ki.2009.103</pub-id>
<pub-id pub-id-type="pmid">19564856</pub-id>
</element-citation>
</ref>
<ref id="CR34">
<label>34.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Alizadeh</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Mirzabeglo</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Is oxytocin a therapeutic factor for ischemic heart disease?</article-title>
<source/>Peptides
          <year>2013</year>
<volume>45</volume>
<fpage>66</fpage>
<lpage>72</lpage>
<pub-id pub-id-type="doi">10.1016/j.peptides.2013.04.016</pub-id>
<pub-id pub-id-type="pmid">23659864</pub-id>
</element-citation>
</ref>
<ref id="CR35">
<label>35.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mukaddam-Daher</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Yin</surname>
<given-names>YL</given-names>
</name>
<name>
<surname>Roy</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Cardinal</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Negative inotropic and chronotropic effects of oxytocin</article-title>
<source/>Hypertension
          <year>2001</year>
<volume>38</volume>
<issue>2</issue>
<fpage>292</fpage>
<lpage>296</lpage>
<pub-id pub-id-type="doi">10.1161/01.HYP.38.2.292</pub-id>
<pub-id pub-id-type="pmid">11509492</pub-id>
</element-citation>
</ref>
<ref id="CR36">
<label>36.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ondrejcakova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ravingerova</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bakos</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Pancza</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Oxytocin exerts protective effects on in vitro myocardial injury induced by ischemia and reperfusion</article-title>
<source/>Can J Physiol Pharmacol
          <year>2009</year>
<volume>87</volume>
<issue>2</issue>
<fpage>137</fpage>
<lpage>142</lpage>
<pub-id pub-id-type="doi">10.1139/Y08-108</pub-id>
<pub-id pub-id-type="pmid">19234577</pub-id>
</element-citation>
</ref>
<ref id="CR37">
<label>37.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ondrejcakova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Barancik</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Bartekova</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Ravingerova</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Jezova</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Prolonged oxytocin treatment in rats affects intracellular signaling and induces myocardial protection against infarction</article-title>
<source/>Gen Physiol Biophys
          <year>2012</year>
<volume>31</volume>
<issue>3</issue>
<fpage>261</fpage>
<lpage>270</lpage>
<pub-id pub-id-type="doi">10.4149/gpb_2012_030</pub-id>
<pub-id pub-id-type="pmid">23047939</pub-id>
</element-citation>
</ref>
<ref id="CR38">
<label>38.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Florian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Oxytocin increases glucose uptake in neonatal rat cardiomyocytes</article-title>
<source/>Endocrinology
          <year>2010</year>
<volume>151</volume>
<issue>2</issue>
<fpage>482</fpage>
<lpage>491</lpage>
<pub-id pub-id-type="doi">10.1210/en.2009-0624</pub-id>
<pub-id pub-id-type="pmid">20008042</pub-id>
</element-citation>
</ref>
<ref id="CR39">
<label>39.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Garlid</surname>
<given-names>KD</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>AD</given-names>
</name>
<name>
<surname>Quinlan</surname>
<given-names>CL</given-names>
</name>
<name>
<surname>Pierre</surname>
<given-names>SV</given-names>
</name>
<name>
<surname>Dos Santos</surname>
<given-names>P</given-names>
</name>
</person-group>
<article-title>Cardioprotective signaling to mitochondria</article-title>
<source/>J Mol Cell Cardiol
          <year>2009</year>
<volume>46</volume>
<issue>6</issue>
<fpage>858</fpage>
<lpage>866</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2008.11.019</pub-id>
<pub-id pub-id-type="pmid">19118560</pub-id>
</element-citation>
</ref>
<ref id="CR40">
<label>40.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daiber</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species</article-title>
<source/>Biochim Biophys Acta
          <year>2010</year>
<volume>1797</volume>
<issue>6-7</issue>
<fpage>897</fpage>
<lpage>906</lpage>
<pub-id pub-id-type="doi">10.1016/j.bbabio.2010.01.032</pub-id>
<pub-id pub-id-type="pmid">20122895</pub-id>
</element-citation>
</ref>
<ref id="CR41">
<label>41.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Perrelli</surname>
<given-names>MG</given-names>
</name>
<name>
<surname>Pagliaro</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Penna</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Ischemia/reperfusion injury and cardioprotective mechanisms: Role of mitochondria and reactive oxygen species</article-title>
<source/>World J Cardiol
          <year>2011</year>
<volume>3</volume>
<issue>6</issue>
<fpage>186</fpage>
<lpage>200</lpage>
<pub-id pub-id-type="doi">10.4330/wjc.v3.i6.186</pub-id>
<pub-id pub-id-type="pmid">21772945</pub-id>
</element-citation>
</ref>
<ref id="CR42">
<label>42.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nishimori</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>LJ</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Insel</surname>
<given-names>TR</given-names>
</name>
<name>
<surname>Matzuk</surname>
<given-names>MM</given-names>
</name>
</person-group>
<article-title>Oxytocin is required for nursing but is not essential for parturition or reproductive behavior</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>1996</year>
<volume>93</volume>
<issue>21</issue>
<fpage>11699</fpage>
<lpage>11704</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.93.21.11699</pub-id>
<pub-id pub-id-type="pmid">8876199</pub-id>
</element-citation>
</ref>
<ref id="CR43">
<label>43.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Bai</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Dean</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Wu</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Neuropeptide exocytosis involving synaptotagmin-4 and oxytocin in hypothalamic programming of body weight and energy balance</article-title>
<source/>Neuron
          <year>2011</year>
<volume>69</volume>
<issue>3</issue>
<fpage>523</fpage>
<lpage>535</lpage>
<pub-id pub-id-type="doi">10.1016/j.neuron.2010.12.036</pub-id>
<pub-id pub-id-type="pmid">21315262</pub-id>
</element-citation>
</ref>
<ref id="CR44">
<label>44.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kujath</surname>
<given-names>AS</given-names>
</name>
<name>
<surname>Quinn</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Elliott</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Varady</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>LeCaire</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Carter</surname>
<given-names>CS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin levels are lower in premenopausal women with type 1 diabetes mellitus compared with matched controls</article-title>
<source/>Diabetes Metab Res Rev
          <year>2015</year>
<volume>31</volume>
<issue>1</issue>
<fpage>102</fpage>
<lpage>112</lpage>
<pub-id pub-id-type="doi">10.1002/dmrr.2577</pub-id>
<pub-id pub-id-type="pmid">25044726</pub-id>
</element-citation>
</ref>
<ref id="CR45">
<label>45.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Qian</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Tang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Sun</surname>
<given-names>W</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Decreased circulating levels of oxytocin in obesity and newly diagnosed type 2 diabetic patients</article-title>
<source/>J Clin Endocrinol Metab
          <year>2014</year>
<volume>99</volume>
<issue>12</issue>
<fpage>4683</fpage>
<lpage>4689</lpage>
<pub-id pub-id-type="doi">10.1210/jc.2014-2206</pub-id>
<pub-id pub-id-type="pmid">25233153</pub-id>
</element-citation>
</ref>
<ref id="CR46">
<label>46.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morton</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Thatcher</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Reidelberger</surname>
<given-names>RD</given-names>
</name>
<name>
<surname>Ogimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Wolden-Hanson</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Baskin</surname>
<given-names>DG</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Peripheral oxytocin suppresses food intake and causes weight loss in diet-induced obese rats</article-title>
<source/>Am J Physiol Endocrinol Metab
          <year>2012</year>
<volume>302</volume>
<issue>1</issue>
<fpage>E134</fpage>
<lpage>144</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00296.2011</pub-id>
<pub-id pub-id-type="pmid">22008455</pub-id>
</element-citation>
</ref>
<ref id="CR47">
<label>47.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Blevins</surname>
<given-names>JE</given-names>
</name>
<name>
<surname>Thompson</surname>
<given-names>BW</given-names>
</name>
<name>
<surname>Anekonda</surname>
<given-names>VT</given-names>
</name>
<name>
<surname>Ho</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Graham</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Roberts</surname>
<given-names>ZS</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Chronic CNS oxytocin signaling preferentially induces fat loss in high-fat diet-fed rats by enhancing satiety responses and increasing lipid utilization</article-title>
<source/>Am J Physiol Regul Integr Comp Physiol
          <year>2016</year>
<volume>310</volume>
<issue>7</issue>
<fpage>R640</fpage>
<lpage>658</lpage>
<pub-id pub-id-type="doi">10.1152/ajpregu.00220.2015</pub-id>
<pub-id pub-id-type="pmid">26791828</pub-id>
</element-citation>
</ref>
<ref id="CR48">
<label>48.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gajdosechova</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Krskova</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Segarra</surname>
<given-names>AB</given-names>
</name>
<name>
<surname>Spolcova</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Suski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Olszanecki</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Hypooxytocinaemia in obese Zucker rats relates to oxytocin degradation in liver and adipose tissue</article-title>
<source/>J Endocrinol
          <year>2014</year>
<volume>220</volume>
<issue>3</issue>
<fpage>333</fpage>
<lpage>343</lpage>
<pub-id pub-id-type="doi">10.1530/JOE-13-0417</pub-id>
<pub-id pub-id-type="pmid">24389591</pub-id>
</element-citation>
</ref>
<ref id="CR49">
<label>49.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plante</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Menaouar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Yip</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Chiasson</surname>
<given-names>JL</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin treatment prevents the cardiomyopathy observed in obese diabetic male db/db mice</article-title>
<source/>Endocrinology
          <year>2015</year>
<volume>156</volume>
<issue>4</issue>
<fpage>1416</fpage>
<lpage>1428</lpage>
<pub-id pub-id-type="doi">10.1210/en.2014-1718</pub-id>
<pub-id pub-id-type="pmid">25562615</pub-id>
</element-citation>
</ref>
<ref id="CR50">
<label>50.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Altirriba</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Poher</surname>
<given-names>AL</given-names>
</name>
<name>
<surname>Caillon</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Arsenijevic</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Veyrat-Durebex</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Lyautey</surname>
<given-names>J</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Divergent effects of oxytocin treatment of obese diabetic mice on adiposity and diabetes</article-title>
<source/>Endocrinology
          <year>2014</year>
<volume>155</volume>
<issue>11</issue>
<fpage>4189</fpage>
<lpage>4201</lpage>
<pub-id pub-id-type="doi">10.1210/en.2014-1466</pub-id>
<pub-id pub-id-type="pmid">25157455</pub-id>
</element-citation>
</ref>
<ref id="CR51">
<label>51.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sabatier</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Leng</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Menzies</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Oxytocin, feeding, and satiety</article-title>
<source/>Front Endocrinol
          <year>2013</year>
<volume>4</volume>
<fpage>35</fpage>
<pub-id pub-id-type="doi">10.3389/fendo.2013.00035</pub-id>
</element-citation>
</ref>
<ref id="CR52">
<label>52.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ingalls</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Dickie</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Snell</surname>
<given-names>GD</given-names>
</name>
</person-group>
<article-title>Obese, a new mutation in the house mouse</article-title>
<source/>J Hered
          <year>1950</year>
<volume>41</volume>
<issue>12</issue>
<fpage>317</fpage>
<lpage>318</lpage>
<pub-id pub-id-type="pmid">14824537</pub-id>
</element-citation>
</ref>
<ref id="CR53">
<label>53.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mazzone</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Intensive glucose lowering and cardiovascular disease prevention in diabetes: reconciling the recent clinical trial data</article-title>
<source/>Circulation
          <year>2010</year>
<volume>122</volume>
<issue>21</issue>
<fpage>2201</fpage>
<lpage>2211</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.109.913350</pub-id>
<pub-id pub-id-type="pmid">21098460</pub-id>
</element-citation>
</ref>
<ref id="CR54">
<label>54.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Neumann</surname>
<given-names>ID</given-names>
</name>
<name>
<surname>Maloumby</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Beiderbeck</surname>
<given-names>DI</given-names>
</name>
<name>
<surname>Lukas</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Landgraf</surname>
<given-names>R</given-names>
</name>
</person-group>
<article-title>Increased brain and plasma oxytocin after nasal and peripheral administration in rats and mice</article-title>
<source/>Psychoneuroendocrinology
          <year>2013</year>
<volume>38</volume>
<issue>10</issue>
<fpage>1985</fpage>
<lpage>1993</lpage>
<pub-id pub-id-type="doi">10.1016/j.psyneuen.2013.03.003</pub-id>
<pub-id pub-id-type="pmid">23579082</pub-id>
</element-citation>
</ref>
<ref id="CR55">
<label>55.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chang</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Barter</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Ebitz</surname>
<given-names>RB</given-names>
</name>
<name>
<surname>Watson</surname>
<given-names>KK</given-names>
</name>
<name>
<surname>Platt</surname>
<given-names>ML</given-names>
</name>
</person-group>
<article-title>Inhaled oxytocin amplifies both vicarious reinforcement and self reinforcement in rhesus macaques (Macaca mulatta)</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2012</year>
<volume>109</volume>
<issue>3</issue>
<fpage>959</fpage>
<lpage>964</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.1114621109</pub-id>
<pub-id pub-id-type="pmid">22215593</pub-id>
</element-citation>
</ref>
<ref id="CR56">
<label>56.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gossen</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hahn</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Westphal</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Prinz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Schultz</surname>
<given-names>RT</given-names>
</name>
<name>
<surname>Grunder</surname>
<given-names>G</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Oxytocin plasma concentrations after single intranasal oxytocin administration - a study in healthy men</article-title>
<source/>Neuropeptides
          <year>2012</year>
<volume>46</volume>
<issue>5</issue>
<fpage>211</fpage>
<lpage>215</lpage>
<pub-id pub-id-type="doi">10.1016/j.npep.2012.07.001</pub-id>
<pub-id pub-id-type="pmid">22884888</pub-id>
</element-citation>
</ref>
<ref id="CR57">
<label>57.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ludwig</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Tobin</surname>
<given-names>VA</given-names>
</name>
<name>
<surname>Callahan</surname>
<given-names>MF</given-names>
</name>
<name>
<surname>Papadaki</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Becker</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Engelmann</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Intranasal application of vasopressin fails to elicit changes in brain immediate early gene expression, neural activity and behavioural performance of rats</article-title>
<source/>J Neuroendocrinol
          <year>2013</year>
<volume>25</volume>
<issue>7</issue>
<fpage>655</fpage>
<lpage>667</lpage>
<pub-id pub-id-type="doi">10.1111/jne.12046</pub-id>
<pub-id pub-id-type="pmid">23656518</pub-id>
</element-citation>
</ref>
<ref id="CR58">
<label>58.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Veening</surname>
<given-names>JG</given-names>
</name>
<name>
<surname>Olivier</surname>
<given-names>B</given-names>
</name>
</person-group>
<article-title>Intranasal administration of oxytocin: behavioral and clinical effects, a review</article-title>
<source/>Neurosci Biobehav Rev
          <year>2013</year>
<volume>37</volume>
<issue>8</issue>
<fpage>1445</fpage>
<lpage>1465</lpage>
<pub-id pub-id-type="doi">10.1016/j.neubiorev.2013.04.012</pub-id>
<pub-id pub-id-type="pmid">23648680</pub-id>
</element-citation>
</ref>
<ref id="CR59">
<label>59.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Meredith</surname>
<given-names>ME</given-names>
</name>
<name>
<surname>Salameh</surname>
<given-names>TS</given-names>
</name>
<name>
<surname>Banks</surname>
<given-names>WA</given-names>
</name>
</person-group>
<article-title>Intranasal Delivery of Proteins and Peptides in the Treatment of Neurodegenerative Diseases</article-title>
<source/>AAPS J
          <year>2015</year>
<volume>17</volume>
<issue>4</issue>
<fpage>780</fpage>
<lpage>787</lpage>
<pub-id pub-id-type="doi">10.1208/s12248-015-9719-7</pub-id>
<pub-id pub-id-type="pmid">25801717</pub-id>
</element-citation>
</ref>
<ref id="CR60">
<label>60.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Vest</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Heneghan</surname>
<given-names>HM</given-names>
</name>
<name>
<surname>Schauer</surname>
<given-names>PR</given-names>
</name>
<name>
<surname>Young</surname>
<given-names>JB</given-names>
</name>
</person-group>
<article-title>Surgical management of obesity and the relationship to cardiovascular disease</article-title>
<source/>Circulation
          <year>2013</year>
<volume>127</volume>
<issue>8</issue>
<fpage>945</fpage>
<lpage>959</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.112.103275</pub-id>
<pub-id pub-id-type="pmid">23439447</pub-id>
</element-citation>
</ref>
<ref id="CR61">
<label>61.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Thompson</surname>
<given-names>PD</given-names>
</name>
<name>
<surname>Buchner</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pina</surname>
<given-names>IL</given-names>
</name>
<name>
<surname>Balady</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Williams</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Marcus</surname>
<given-names>BH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exercise and physical activity in the prevention and treatment of atherosclerotic cardiovascular disease: a statement from the Council on Clinical Cardiology (Subcommittee on Exercise, Rehabilitation, and Prevention) and the Council on Nutrition, Physical Activity, and Metabolism (Subcommittee on Physical Activity)</article-title>
<source/>Circulation
          <year>2003</year>
<volume>107</volume>
<issue>24</issue>
<fpage>3109</fpage>
<lpage>3116</lpage>
<pub-id pub-id-type="doi">10.1161/01.CIR.0000075572.40158.77</pub-id>
<pub-id pub-id-type="pmid">12821592</pub-id>
</element-citation>
</ref>
<ref id="CR62">
<label>62.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bassuk</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Manson</surname>
<given-names>JE</given-names>
</name>
</person-group>
<article-title>Epidemiological evidence for the role of physical activity in reducing risk of type 2 diabetes and cardiovascular disease</article-title>
<source/>J Appl Physiol
          <year>2005</year>
<volume>99</volume>
<issue>3</issue>
<fpage>1193</fpage>
<lpage>1204</lpage>
<pub-id pub-id-type="doi">10.1152/japplphysiol.00160.2005</pub-id>
<pub-id pub-id-type="pmid">16103522</pub-id>
</element-citation>
</ref>
<ref id="CR63">
<label>63.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lavie</surname>
<given-names>CJ</given-names>
</name>
<name>
<surname>Arena</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Swift</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Johannsen</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Sui</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>DC</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exercise and the cardiovascular system: clinical science and cardiovascular outcomes</article-title>
<source/>Circ Res
          <year>2015</year>
<volume>117</volume>
<issue>2</issue>
<fpage>207</fpage>
<lpage>219</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.117.305205</pub-id>
<pub-id pub-id-type="pmid">26139859</pub-id>
</element-citation>
</ref>
<ref id="CR64">
<label>64.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Halaas</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gajiwala</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Maffei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Cohen</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Chait</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Rabinowitz</surname>
<given-names>D</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Weight-reducing effects of the plasma protein encoded by the obese gene</article-title>
<source/>Science
          <year>1995</year>
<volume>269</volume>
<issue>5223</issue>
<fpage>543</fpage>
<lpage>546</lpage>
<pub-id pub-id-type="doi">10.1126/science.7624777</pub-id>
<pub-id pub-id-type="pmid">7624777</pub-id>
</element-citation>
</ref>
<ref id="CR65">
<label>65.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Maffei</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Halaas</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ravussin</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Pratley</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>GH</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects</article-title>
<source/>Nat Med
          <year>1995</year>
<volume>1</volume>
<issue>11</issue>
<fpage>1155</fpage>
<lpage>1161</lpage>
<pub-id pub-id-type="doi">10.1038/nm1195-1155</pub-id>
<pub-id pub-id-type="pmid">7584987</pub-id>
</element-citation>
</ref>
<ref id="CR66">
<label>66.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gollisch</surname>
<given-names>KS</given-names>
</name>
<name>
<surname>Brandauer</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Jessen</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Toyoda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Nayer</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Hirshman</surname>
<given-names>MF</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Effects of exercise training on subcutaneous and visceral adipose tissue in normal- and high-fat diet-fed rats</article-title>
<source/>Am J Physiol Endocrinol Metab
          <year>2009</year>
<volume>297</volume>
<issue>2</issue>
<fpage>E495</fpage>
<lpage>504</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.90424.2008</pub-id>
<pub-id pub-id-type="pmid">19491293</pub-id>
</element-citation>
</ref>
<ref id="CR67">
<label>67.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Schwartz</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Prigeon</surname>
<given-names>RL</given-names>
</name>
<name>
<surname>Kahn</surname>
<given-names>SE</given-names>
</name>
<name>
<surname>Nicolson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Moore</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Morawiecki</surname>
<given-names>A</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence that plasma leptin and insulin levels are associated with body adiposity via different mechanisms</article-title>
<source/>Diabetes Care
          <year>1997</year>
<volume>20</volume>
<issue>9</issue>
<fpage>1476</fpage>
<lpage>1481</lpage>
<pub-id pub-id-type="doi">10.2337/diacare.20.9.1476</pub-id>
<pub-id pub-id-type="pmid">9283801</pub-id>
</element-citation>
</ref>
<ref id="CR68">
<label>68.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Romero-Corral</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Sierra-Johnson</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Lopez-Jimenez</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Thomas</surname>
<given-names>RJ</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Hoffmann</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Relationships between leptin and C-reactive protein with cardiovascular disease in the adult general population</article-title>
<source/>Nat Clin Pract Cardiovasc Med
          <year>2008</year>
<volume>5</volume>
<issue>7</issue>
<fpage>418</fpage>
<lpage>425</lpage>
<pub-id pub-id-type="doi">10.1038/ncpcardio1218</pub-id>
<pub-id pub-id-type="pmid">18431365</pub-id>
</element-citation>
</ref>
<ref id="CR69">
<label>69.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Martin</surname>
<given-names>SS</given-names>
</name>
<name>
<surname>Qasim</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Reilly</surname>
<given-names>MP</given-names>
</name>
</person-group>
<article-title>Leptin resistance: a possible interface of inflammation and metabolism in obesity-related cardiovascular disease</article-title>
<source/>J Am Coll Cardiol
          <year>2008</year>
<volume>52</volume>
<issue>15</issue>
<fpage>1201</fpage>
<lpage>1210</lpage>
<pub-id pub-id-type="doi">10.1016/j.jacc.2008.05.060</pub-id>
<pub-id pub-id-type="pmid">18926322</pub-id>
</element-citation>
</ref>
<ref id="CR70">
<label>70.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rabe</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Lehrke</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Parhofer</surname>
<given-names>KG</given-names>
</name>
<name>
<surname>Broedl</surname>
<given-names>UC</given-names>
</name>
</person-group>
<article-title>Adipokines and insulin resistance</article-title>
<source/>Mol Med
          <year>2008</year>
<volume>14</volume>
<issue>11-12</issue>
<fpage>741</fpage>
<lpage>751</lpage>
<pub-id pub-id-type="doi">10.2119/2008-00058.Rabe</pub-id>
<pub-id pub-id-type="pmid">19009016</pub-id>
</element-citation>
</ref>
<ref id="CR71">
<label>71.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zachwieja</surname>
<given-names>JJ</given-names>
</name>
<name>
<surname>Hendry</surname>
<given-names>SL</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>SR</given-names>
</name>
<name>
<surname>Harris</surname>
<given-names>RB</given-names>
</name>
</person-group>
<article-title>Voluntary wheel running decreases adipose tissue mass and expression of leptin mRNA in Osborne-Mendel rats</article-title>
<source/>Diabetes
          <year>1997</year>
<volume>46</volume>
<issue>7</issue>
<fpage>1159</fpage>
<lpage>1166</lpage>
<pub-id pub-id-type="doi">10.2337/diab.46.7.1159</pub-id>
<pub-id pub-id-type="pmid">9200651</pub-id>
</element-citation>
</ref>
<ref id="CR72">
<label>72.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Moien-Afshari</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Ghosh</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Elmi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Rahman</surname>
<given-names>MM</given-names>
</name>
<name>
<surname>Sallam</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Khazaei</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Exercise restores endothelial function independently of weight loss or hyperglycaemic status in db/db mice</article-title>
<source/>Diabetologia
          <year>2008</year>
<volume>51</volume>
<issue>7</issue>
<fpage>1327</fpage>
<lpage>1337</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-008-0996-x</pub-id>
<pub-id pub-id-type="pmid">18437348</pub-id>
</element-citation>
</ref>
<ref id="CR73">
<label>73.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sakurai</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Ogasawara</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kizaki</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sato</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Ishibashi</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Takahashi</surname>
<given-names>M</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The effects of exercise training on obesity-induced dysregulated expression of adipokines in white adipose tissue</article-title>
<source/>Int J Endocrinol
          <year>2013</year>
<volume>2013</volume>
<fpage>801743</fpage>
<pub-id pub-id-type="doi">10.1155/2013/801743</pub-id>
<pub-id pub-id-type="pmid">24369466</pub-id>
</element-citation>
</ref>
<ref id="CR74">
<label>74.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Bogdan</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Lavoie</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Downregulation of oxytocin and natriuretic peptides in diabetes: possible implications in cardiomyopathy</article-title>
<source/>J Physiol
          <year>2009</year>
<volume>587</volume>
<issue>Pt 19</issue>
<fpage>4725</fpage>
<lpage>4736</lpage>
<pub-id pub-id-type="doi">10.1113/jphysiol.2009.176461</pub-id>
<pub-id pub-id-type="pmid">19675071</pub-id>
</element-citation>
</ref>
<ref id="CR75">
<label>75.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
</person-group>
<article-title>Downregulation of oxytocin receptors in right ventricle of rats with monocrotaline-induced pulmonary hypertension</article-title>
<source/>Acta Physiol (Oxf)
          <year>2010</year>
<volume>200</volume>
<issue>2</issue>
<fpage>147</fpage>
<lpage>158</lpage>
<pub-id pub-id-type="doi">10.1111/j.1748-1716.2010.02134.x</pub-id>
<pub-id pub-id-type="pmid">20377540</pub-id>
</element-citation>
</ref>
<ref id="CR76">
<label>76.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Grewen</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>Light</surname>
<given-names>KC</given-names>
</name>
</person-group>
<article-title>Plasma oxytocin is related to lower cardiovascular and sympathetic reactivity to stress</article-title>
<source/>Biol Psychol
          <year>2011</year>
<volume>87</volume>
<issue>3</issue>
<fpage>340</fpage>
<lpage>349</lpage>
<pub-id pub-id-type="doi">10.1016/j.biopsycho.2011.04.003</pub-id>
<pub-id pub-id-type="pmid">21540072</pub-id>
</element-citation>
</ref>
<ref id="CR77">
<label>77.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kobayashi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Mao</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Zheng</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Patterson</surname>
<given-names>C</given-names>
</name>
<name>
<surname>O’Connell</surname>
<given-names>TD</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diminished GATA4 protein levels contribute to hyperglycemia-induced cardiomyocyte injury</article-title>
<source/>J Biol Chem
          <year>2007</year>
<volume>282</volume>
<issue>30</issue>
<fpage>21945</fpage>
<lpage>21952</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.M703048200</pub-id>
<pub-id pub-id-type="pmid">17525155</pub-id>
</element-citation>
</ref>
<ref id="CR78">
<label>78.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Molkentin</surname>
<given-names>JD</given-names>
</name>
</person-group>
<article-title>The zinc finger-containing transcription factors GATA-4, -5, and -6. Ubiquitously expressed regulators of tissue-specific gene expression</article-title>
<source/>J Biol Chem
          <year>2000</year>
<volume>275</volume>
<issue>50</issue>
<fpage>38949</fpage>
<lpage>38952</lpage>
<pub-id pub-id-type="doi">10.1074/jbc.R000029200</pub-id>
<pub-id pub-id-type="pmid">11042222</pub-id>
</element-citation>
</ref>
<ref id="CR79">
<label>79.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Parrott</surname>
<given-names>CR</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Downregulation in GATA4 and Downstream Structural and Contractile Genes in the db/db Mouse Heart</article-title>
<source/>ISRN endocrinol
          <year>2012</year>
<volume>2012</volume>
<fpage>736860</fpage>
<pub-id pub-id-type="pmid">22474596</pub-id>
</element-citation>
</ref>
<ref id="CR80">
<label>80.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Lee</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Dai</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Mitch</surname>
<given-names>WE</given-names>
</name>
</person-group>
<article-title>Regulation of muscle protein degradation: coordinated control of apoptotic and ubiquitin-proteasome systems by phosphatidylinositol 3 kinase</article-title>
<source/>J Am Soc Nephrol: JASN
          <year>2004</year>
<volume>15</volume>
<issue>6</issue>
<fpage>1537</fpage>
<lpage>1545</lpage>
<pub-id pub-id-type="doi">10.1097/01.ASN.0000127211.86206.E1</pub-id>
<pub-id pub-id-type="pmid">15153564</pub-id>
</element-citation>
</ref>
<ref id="CR81">
<label>81.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adams</surname>
<given-names>V</given-names>
</name>
<name>
<surname>Mangner</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gasch</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Krohne</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Gielen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hirner</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Induction of MuRF1 is essential for TNF-alpha-induced loss of muscle function in mice</article-title>
<source/>J Mol Biol
          <year>2008</year>
<volume>384</volume>
<issue>1</issue>
<fpage>48</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.jmb.2008.08.087</pub-id>
<pub-id pub-id-type="pmid">18804115</pub-id>
</element-citation>
</ref>
<ref id="CR82">
<label>82.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Plante</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Menaouar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Treatment with brain natriuretic peptide prevents the development of cardiac dysfunction in obese diabetic db/db mice</article-title>
<source/>Diabetologia
          <year>2014</year>
<volume>57</volume>
<issue>6</issue>
<fpage>1257</fpage>
<lpage>1267</lpage>
<pub-id pub-id-type="doi">10.1007/s00125-014-3201-4</pub-id>
<pub-id pub-id-type="pmid">24595856</pub-id>
</element-citation>
</ref>
<ref id="CR83">
<label>83.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>Unexpected effects of voluntary exercise training on natriuretic peptide and receptor mRNA expression in the ob/ob mouse heart</article-title>
<source/>Regul Pept
          <year>2014</year>
<volume>188</volume>
<fpage>52</fpage>
<lpage>59</lpage>
<pub-id pub-id-type="doi">10.1016/j.regpep.2013.12.005</pub-id>
<pub-id pub-id-type="pmid">24365091</pub-id>
</element-citation>
</ref>
<ref id="CR84">
<label>84.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morton</surname>
<given-names>GJ</given-names>
</name>
<name>
<surname>Kaiyala</surname>
<given-names>KJ</given-names>
</name>
<name>
<surname>Fisher</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Ogimoto</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Schwartz</surname>
<given-names>MW</given-names>
</name>
<name>
<surname>Wisse</surname>
<given-names>BE</given-names>
</name>
</person-group>
<article-title>Identification of a physiological role for leptin in the regulation of ambulatory activity and wheel running in mice</article-title>
<source/>Am J Physiol Endocrinol Metab
          <year>2011</year>
<volume>300</volume>
<issue>2</issue>
<fpage>E392</fpage>
<lpage>401</lpage>
<pub-id pub-id-type="doi">10.1152/ajpendo.00546.2010</pub-id>
<pub-id pub-id-type="pmid">21062956</pub-id>
</element-citation>
</ref>
<ref id="CR85">
<label>85.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bisping</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Ikeda</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Kong</surname>
<given-names>SW</given-names>
</name>
<name>
<surname>Tarnavski</surname>
<given-names>O</given-names>
</name>
<name>
<surname>Bodyak</surname>
<given-names>N</given-names>
</name>
<name>
<surname>McMullen</surname>
<given-names>JR</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Gata4 is required for maintenance of postnatal cardiac function and protection from pressure overload-induced heart failure</article-title>
<source/>Proc Natl Acad Sci U S A
          <year>2006</year>
<volume>103</volume>
<issue>39</issue>
<fpage>14471</fpage>
<lpage>14476</lpage>
<pub-id pub-id-type="doi">10.1073/pnas.0602543103</pub-id>
<pub-id pub-id-type="pmid">16983087</pub-id>
</element-citation>
</ref>
<ref id="CR86">
<label>86.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shannon</surname>
<given-names>RP</given-names>
</name>
</person-group>
<article-title>Insulin resistance in dilated cardiomyopathy</article-title>
<source/>Rev Cardiovasc Med
          <year>2003</year>
<volume>4</volume>
<issue>Suppl 6</issue>
<fpage>S50</fpage>
<lpage>57</lpage>
<pub-id pub-id-type="pmid">14668703</pub-id>
</element-citation>
</ref>
<ref id="CR87">
<label>87.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Manolescu</surname>
<given-names>DC</given-names>
</name>
<name>
<surname>Jankowski</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Danalache</surname>
<given-names>BA</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Broderick</surname>
<given-names>TL</given-names>
</name>
<name>
<surname>Chiasson</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Gutkowska</surname>
<given-names>J</given-names>
</name>
</person-group>
<article-title>All-trans retinoic acid stimulates gene expression of the cardioprotective natriuretic peptide system and prevents fibrosis and apoptosis in cardiomyocytes of obese ob/ob mice</article-title>
<source/>Appl Physiol Nutr Metab = Physiologie appliquee, nutrition et metabolisme
          <year>2014</year>
<volume>39</volume>
<issue>10</issue>
<fpage>1127</fpage>
<lpage>1136</lpage>
<pub-id pub-id-type="doi">10.1139/apnm-2014-0005</pub-id>
<pub-id pub-id-type="pmid">25017112</pub-id>
</element-citation>
</ref>
<ref id="CR88">
<label>88.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Beltrami</surname>
<given-names>AP</given-names>
</name>
<name>
<surname>Urbanek</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kajstura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yan</surname>
<given-names>SM</given-names>
</name>
<name>
<surname>Finato</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Bussani</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Evidence that human cardiac myocytes divide after myocardial infarction</article-title>
<source/>N Engl J Med
          <year>2001</year>
<volume>344</volume>
<issue>23</issue>
<fpage>1750</fpage>
<lpage>1757</lpage>
<pub-id pub-id-type="doi">10.1056/NEJM200106073442303</pub-id>
<pub-id pub-id-type="pmid">11396441</pub-id>
</element-citation>
</ref>
<ref id="CR89">
<label>89.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bollini</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Smart</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Riley</surname>
<given-names>PR</given-names>
</name>
</person-group>
<article-title>Resident cardiac progenitor cells: at the heart of regeneration</article-title>
<source/>J Mol Cell Cardiol
          <year>2011</year>
<volume>50</volume>
<issue>2</issue>
<fpage>296</fpage>
<lpage>303</lpage>
<pub-id pub-id-type="doi">10.1016/j.yjmcc.2010.07.006</pub-id>
<pub-id pub-id-type="pmid">20643135</pub-id>
</element-citation>
</ref>
<ref id="CR90">
<label>90.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>D’Amario</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Leone</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Iaconelli</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Luciani</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Gaudino</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Kannappan</surname>
<given-names>R</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Growth properties of cardiac stem cells are a novel biomarker of patients’ outcome after coronary bypass surgery</article-title>
<source/>Circulation
          <year>2014</year>
<volume>129</volume>
<issue>2</issue>
<fpage>157</fpage>
<lpage>172</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.113.006591</pub-id>
<pub-id pub-id-type="pmid">24249720</pub-id>
</element-citation>
</ref>
<ref id="CR91">
<label>91.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zabala</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Calpe</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Perez</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Lerin</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Mouronval</surname>
<given-names>L</given-names>
</name>
</person-group>
<article-title>Neutropenia, thrombocytopenia and hepatic injury associated with dexketoprofen trometamol therapy in a previously healthy 35-year-old woman</article-title>
<source/>J Clin Pharm Ther
          <year>2008</year>
<volume>33</volume>
<issue>1</issue>
<fpage>79</fpage>
<lpage>81</lpage>
<pub-id pub-id-type="doi">10.1111/j.1365-2710.2008.00881.x</pub-id>
<pub-id pub-id-type="pmid">18211621</pub-id>
</element-citation>
</ref>
<ref id="CR92">
<label>92.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Jialal</surname>
<given-names>I</given-names>
</name>
<name>
<surname>Fadini</surname>
<given-names>GP</given-names>
</name>
<name>
<surname>Pollock</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Devaraj</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Circulating levels of endothelial progenitor cell mobilizing factors in the metabolic syndrome</article-title>
<source/>Am J Cardiol
          <year>2010</year>
<volume>106</volume>
<issue>11</issue>
<fpage>1606</fpage>
<lpage>1608</lpage>
<pub-id pub-id-type="doi">10.1016/j.amjcard.2010.07.039</pub-id>
<pub-id pub-id-type="pmid">21040691</pub-id>
</element-citation>
</ref>
<ref id="CR93">
<label>93.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kajstura</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Bearzi</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Rota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Maestroni</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Urbanek</surname>
<given-names>K</given-names>
</name>
<etal></etal>
</person-group>
<article-title>The human heart: a self-renewing organ</article-title>
<source/>Clin Transl Sci
          <year>2008</year>
<volume>1</volume>
<issue>1</issue>
<fpage>80</fpage>
<lpage>86</lpage>
<pub-id pub-id-type="doi">10.1111/j.1752-8062.2008.00030.x</pub-id>
<pub-id pub-id-type="pmid">20443822</pub-id>
</element-citation>
</ref>
<ref id="CR94">
<label>94.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Rota</surname>
<given-names>M</given-names>
</name>
<name>
<surname>LeCapitaine</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Hosoda</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Boni</surname>
<given-names>A</given-names>
</name>
<name>
<surname>De Angelis</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Padin-Iruegas</surname>
<given-names>ME</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Diabetes promotes cardiac stem cell aging and heart failure, which are prevented by deletion of the p66shc gene</article-title>
<source/>Circ Res
          <year>2006</year>
<volume>99</volume>
<issue>1</issue>
<fpage>42</fpage>
<lpage>52</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.0000231289.63468.08</pub-id>
<pub-id pub-id-type="pmid">16763167</pub-id>
</element-citation>
</ref>
<ref id="CR95">
<label>95.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Messina</surname>
<given-names>E</given-names>
</name>
<name>
<surname>Giacomello</surname>
<given-names>A</given-names>
</name>
</person-group>
<article-title>Diabetic cardiomyopathy: a “cardiac stem cell disease” involving p66Shc, an attractive novel molecular target for heart failure therapy</article-title>
<source/>Circ Res
          <year>2006</year>
<volume>99</volume>
<issue>1</issue>
<fpage>1</fpage>
<lpage>2</lpage>
<pub-id pub-id-type="doi">10.1161/01.RES.0000233141.65522.3e</pub-id>
<pub-id pub-id-type="pmid">16825582</pub-id>
</element-citation>
</ref>
<ref id="CR96">
<label>96.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mohsin</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Khan</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Nguyen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Alkatib</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Siddiqi</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hariharan</surname>
<given-names>N</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Rejuvenation of human cardiac progenitor cells with Pim-1 kinase</article-title>
<source/>Circ Res
          <year>2013</year>
<volume>113</volume>
<issue>10</issue>
<fpage>1169</fpage>
<lpage>1179</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.302302</pub-id>
<pub-id pub-id-type="pmid">24044948</pub-id>
</element-citation>
</ref>
<ref id="CR97">
<label>97.</label>
<mixed-citation publication-type="other">Emmert MY, Emmert LS, Martens A, Ismail I, Schmidt-Richter I, Gawol A, Seifert B, Haverich A, Martin U, Gruh I. Higher frequencies of BCRP+ cardiac resident cells in ischaemic human myocardium. Eur Heart J. 2013;34(36):2830–8. doi:10.1093/eurheartj/ehs156.</mixed-citation>
</ref>
<ref id="CR98">
<label>98.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Noiseux</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Borie</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Desnoyers</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Menaouar</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Stevens</surname>
<given-names>LM</given-names>
</name>
<name>
<surname>Mansour</surname>
<given-names>S</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Preconditioning of stem cells by oxytocin to improve their therapeutic potential</article-title>
<source/>Endocrinology
          <year>2012</year>
<volume>153</volume>
<issue>11</issue>
<fpage>5361</fpage>
<lpage>5372</lpage>
<pub-id pub-id-type="doi">10.1210/en.2012-1402</pub-id>
<pub-id pub-id-type="pmid">23024264</pub-id>
</element-citation>
</ref>
<ref id="CR99">
<label>99.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Williams</surname>
<given-names>AR</given-names>
</name>
<name>
<surname>Hare</surname>
<given-names>JM</given-names>
</name>
</person-group>
<article-title>Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease</article-title>
<source/>Circ Res
          <year>2011</year>
<volume>109</volume>
<issue>8</issue>
<fpage>923</fpage>
<lpage>940</lpage>
<pub-id pub-id-type="doi">10.1161/CIRCRESAHA.111.243147</pub-id>
<pub-id pub-id-type="pmid">21960725</pub-id>
</element-citation>
</ref>
<ref id="CR100">
<label>100.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kim</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>CH</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>MH</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Promigratory activity of oxytocin on umbilical cord blood-derived mesenchymal stem cells</article-title>
<source/>Artif Organs
          <year>2010</year>
<volume>34</volume>
<issue>6</issue>
<fpage>453</fpage>
<lpage>461</lpage>
<pub-id pub-id-type="doi">10.1111/j.1525-1594.2009.00894.x</pub-id>
<pub-id pub-id-type="pmid">20624160</pub-id>
</element-citation>
</ref>
<ref id="CR101">
<label>101.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Kim</surname>
<given-names>YS</given-names>
</name>
<name>
<surname>Kwon</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Hong</surname>
<given-names>MH</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>WS</given-names>
</name>
<name>
<surname>Jeong</surname>
<given-names>HY</given-names>
</name>
<name>
<surname>Kang</surname>
<given-names>HJ</given-names>
</name>
<etal></etal>
</person-group>
<article-title>Restoration of angiogenic capacity of diabetes-insulted mesenchymal stem cells by oxytocin</article-title>
<source/>BMC cell biol
          <year>2013</year>
<volume>14</volume>
<fpage>38</fpage>
<pub-id pub-id-type="doi">10.1186/1471-2121-14-38</pub-id>
<pub-id pub-id-type="pmid">24024790</pub-id>
</element-citation>
</ref>
<ref id="CR102">
<label>102.</label>
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Forbes</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Cooper</surname>
<given-names>ME</given-names>
</name>
</person-group>
<article-title>Mechanisms of diabetic complications</article-title>
<source/>Physiol Rev
          <year>2013</year>
<volume>93</volume>
<issue>1</issue>
<fpage>137</fpage>
<lpage>188</lpage>
<pub-id pub-id-type="doi">10.1152/physrev.00045.2011</pub-id>
<pub-id pub-id-type="pmid">23303908</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
</article>
</pmc-articleset>